Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT

//Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT

Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT

Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors (PET/Ga68)

Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE injection in patients with suspected or diagnosed with tumors expressing somatostatin receptors.

This study is open and currently recruiting patients.

Location:
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4

Contacts:
Principal Investigator: Eric Turcotte, MD
Helena Senta, PhD 819-346-1110 ext 13660 helena.senta@usherbrooke.ca

For more information on this trial: NCT02810600

By | 2018-05-07T18:28:13+00:00 June 29th, 2016|Clinical Trial|Comments Off on Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT

About the Author: